Publication Name	World Journal of Clinical Oncology
Manuscript ID	22547
Country	France

Received	2015-09-02 11:56
Peer-Review Started	2015-09-08 11:32
To Make the First Decision	2015-10-08 16:40
Return for Revision	2015-10-16 19:54
Revised	2015-10-23 22:39
Second Decision	2015-12-17 18:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-01-04 17:13
Articles in Press	2016-01-04 17:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-28 14:16
Publish the Manuscript Online	2016-04-07 11:01

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Off-label use of targeted therapies in oncology
Manuscript Source	Invited Manuscript
All Author List	Dominique Levêque
Funding Agency and Grant Number
Corresponding Author	Dominique Levêque, PhD, Division of Pharmacy, hôpital Hautepierre, avenue Molière, 67000 Strasbourg, France. dominique.leveque@chru-strasbourg.fr
Key Words	Targeted therapy; Monoclonal antibody; Off-label anticancer drug use; Reimbursement; Enzyme inhibitor
Core Tip	Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics. This review is the first one focussing on the off-label use of targeted therapies in oncology. When compared with older agents, off-label use of targeted therapies is probably more rational through tumoral genotyping but is faced with a limited clinical support, reimbursement challenges related to the very high pricing and the cost of genotyping or molecular profiling, when applicable.
Publish Date	2016-04-07 11:01
Citation	Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol 2016; 7(2): 253-257
URL	http://www.wjgnet.com/2218-4333/full/v7/i2/253.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i2.253

Full Article (PDF)	WJCO-7-253.pdf
Full Article (Word)	WJCO-7-253.doc
Manuscript File	22547-Review.doc
Answering Reviewers	22547-Answering reviewers.pdf
Audio Core Tip	22547-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	22547-Conflict-of-interest statement.pdf
Copyright License Agreement	22547-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	22547-Language certificate.pdf
Peer-review Report	22547-Peer-review(s).pdf
Scientific Misconduct Check	22547-Scientific misconduct check.pdf
Scientific Editor Work List	22547-Scientific editor work list.pdf